Insulin manufacturers jack up the prices

The price of insulin, a drug that 30 million diabetics in the US need to stay alive, rose dramatically in the 21st century, to $450 a month by 2016. The “big three” insulin manufacturers, Eli Lilly, Novo Nordisk, and Sanofi, have raised their prices year after year by slightly adjusting their insulin formulations to get new patents and avoid generic competition. They call it “innovation,” we call it corruption.

SOURCES: Jean Fuglesten Biniek and William Johnson, The Health Care Cost Institute; Jing Luo, Aaron S Kesselheim, Jeremy Greene, and Kasia J Lipska; The Lancet

More Shkreli Awards: Archives | Current Year